Why the study?
Long noncoding RNAs are implicated in diverse kidney diseases and may represent unexploited therapeutic targets, but questions regarding their functionality and impact remain to be carefully addressed.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
No immediate practice change for diabetic nephropathy; leaves open lncRNA targeting as a hypothesis-generating research avenue.
Recent advances in large-scale RNA sequencing and genome-wide profiling projects have unraveled a heterogeneous group of RNAs, collectively known as long noncoding RNAs (lncRNAs), which play central roles in many diverse biological processes. Importantly, an association between aberrant expression of lncRNAs and diverse human pathologies has been reported, including in a variety of kidney diseases. These observations have raised the possibility that lncRNAs may represent unexploited potential therapeutic targets for kidney diseases. Several important questions regarding the functionality of lncRNAs and their impact in kidney diseases, however, remain to be carefully addressed. Here, we provide an overview of the main functions and mechanisms of actions of lncRNAs, and their promise as therapeutic targets in kidney diseases, emphasizing on the role of some of the best-characterized lncRNAs implicated in the pathogenesis and progression of diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Coellar et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: